Heather A. Hirsch, Ph.D., et al. Integrated genomics and histology based studies of triple negative breast cancer identify ICOS as potential target for therapeutic intervention. Presented at AACR Annual Meeting, April 16, 2018.
Jounce Therapeutics, Inc.
780 Memorial Drive
Cambridge, MA 02139
Phone: (857) 259-3840
Fax: (888) 459-2940
For Investor and Media inquiries, please contact:
(857) 259-3853 email@example.com